Chrome Plugin Live! Redefine the way you read FinTwit š Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
GMTX
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
prnewswire.com
less than 1 hour ago
prnewswire.com
5 hours ago
investorplace.com
12 hours ago
benzinga.com
13 hours ago
Quote Panel
Key Metrics
Forecast
2025-Revenue
2025-EPS
2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
N/A(N/A)
Number of analyst
N/A
Last analyst upgrade/downgrade
Zacks Investment Research
upgradePrevious: Not converted
2022-04-26
Now: Buy
Relative Strength
GMTX
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Earnings Growth
N/A
Current
Estimates
Q2.23
N/A
NA
vsĀ NA
Q3.23
N/A
NA
vsĀ NA
Q4.23
N/A
NA
vsĀ NA
Q1.24
N/A
NA
vsĀ NA
Q2.24
N/A
NA
vsĀ NA
Q3.24
N/A
NA
vsĀ NA
Q4.24
N/A
NA
vsĀ NA
Q1.25
N/A
NA
vsĀ NA
Q2.25
N/A
NA
vsĀ NA
Q3.25
N/A
NA
vsĀ NA
Sales Growth
N/A
Current
Estimates
Q2.23
NA
NAĀ vsĀ NA
Q3.23
NA
NAĀ vsĀ NA
Q4.23
NA
NAĀ vsĀ NA
Q1.24
NA
NAĀ vsĀ NA
Q2.24
NA
NAĀ vsĀ NA
Q3.24
NA
NAĀ vsĀ NA
Q4.24
NA
NAĀ vsĀ NA
Q1.25
NA
NAĀ vsĀ NA
Q2.25
NA
NAĀ vsĀ NA
Q3.25
NA
NAĀ vsĀ NA
Return on Equity
N/A
Q2.23
NA
NA
vsĀ NA
Q3.23
NA
NA
vsĀ NA
Q4.23
NA
NA
vsĀ NA
Q1.24
NA
NA
vsĀ NA
Q2.24
NA
NA
vsĀ NA
Q3.24
NA
NA
vsĀ NA
Q4.24
NA
NA
vsĀ NA
Q1.25
NA
NA
vsĀ NA
Q2.25
NA
NA
vsĀ NA
Q3.25
NA
NA
vsĀ NA
Institutionnal Ownership
QoQ
Q3.20
NA
NA
vsĀ NA
NA
Q4.20
NA
NA
vsĀ NA
NA
Q1.21
52
52
vsĀ NA
NA
Q2.21
64
64
vsĀ 52
23%
Q3.21
70
70
vsĀ 64
9%
Q4.21
62
62
vsĀ 70
-11%
Q1.22
56
56
vsĀ 62
-10%
Q2.22
46
46
vsĀ 56
-18%
Q3.22
44
44
vsĀ 46
-4%
Q4.22
1
1
vsĀ 44
-98%
N/A
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
NASDAQ
After-hours NaN$
0.00 (0.00%)
Relative Strenght
Volume Buzz
170%
Earning Acce
No
Dist 52w H.
95%Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How GMTX compares to sector?
GMTX
0x
